Sareum Holdings (SAR)

 

SAR Share PerformanceMore

52 week high1.7250 28/09/16
52 week low0.6051 27/09/16
52 week change 0.2650 (41.73%)
4 week volume122,537,564 29/08/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Sierra Oncology to host call on Chk1 inhibitor

RNS Number: 0247R Sareum Holdings PLC 18 September 2017 (AIM: SAR) 18 September 2017 SAREUM HOLDINGS PLC ("Sareum" or "the Company") Sierra Oncology to host Key Opinion Leader call with Thomas Helleday, PhD on DNA Damage Response Targets, on Tuesday 19 September Sareum Holdings plc (AIM: SAR) , the specialist cancer drug discovery an...

Sareum profit after tax anticipated to beat expectations

Sareum said it expects profit for the year after tax and cash at bank, for its results for the year to 30 June 2017, to be ahead...

Pre-Close Trading Statement

RNS Number: 5815O Sareum Holdings PLC 22 August 2017 (AIM: SAR) 22 August 2017 SAREUM HOLDINGS PLC ("Sareum" or "the Company") Pre-Close Trading Statement Sareum Holdings plc (AIM: SAR) , the specialist cancer drug discovery and development business, provides the following trading update ahead of its full year results for the year ending 30 Jun...

Sareum to Present at the ICCS 2017

RNS Number: 3717I Sareum Holdings PLC 19 June 2017 (AIM: SAR) Sareum Holdings PLC ("Sareum" or the "Company") Sareum to Present at the International Cancer Cluster Showcase 2017 Dr Tim Mitchell, CEO of Sareum Holdings plc (AIM:SAR), the specialist cancer drug discovery and development business, will deliver a presentation at the 6th annual Internatio...

Sareum updates on Chk1 inhibitor trials

Sareum Holdings has confirmed that it has noted the announcement made today by Sierra Oncology, Inc. reporting on the...

Chk1 Clinical Trials Update

RNS Number: 1628H Sareum Holdings PLC 05 June 2017 (AIM: SAR) 5 June 2017 SAREUM HOLDINGS PLC ("Sareum" or "the Company") Chk1 Clinical Trials Update Sierra Oncology Reports Encouraging Initial Progress from Ongoing Phase 1 Clinical Trials Sareum Holdings plc (AIM:SAR), the specialist cancer drug discovery and development company, notes an...

Sareum Holdings notes Sierra Oncology patents

Sareum Holdings notes an announcement made by Sierra Oncology Inc yesterday that selection patents that explicitly prot...

Sierra Oncology Granted US and EU Patents

RNS Number: 6039G Sareum Holdings PLC 31 May 2017 (AIM: SAR) 31 May 2017 SAREUM HOLDINGS PLC ("Sareum" or "the Company") Sierra Oncology Granted US and EU Patents for Chk1 inhibitor SRA737 Sareum Holdings plc (AIM:SAR), the specialist cancer drug discovery and development company, notes an announcement made by Sierra Oncology, Inc. ...

Fundamental DataMore

EPS-0.04
Dividend yield0 %

Equity Research (SAR)

Sareum Holdings plc
19/09/2017
and Intermediaries Offer to 1 August 2017. The Company may bring forward this closing date at any time. Admission 15 September 2017 Breakfast buffet Sareum Holdings* (SAR.L) 0.85p £22.5m “Sareum...
Sareum Holdings plc
23/08/2017
The specialist cancer drug discovery and development business has updated on trading for the year ended 30 June 2017. Sareum now expects that subject to audit, net profit and cash balances will be...
Sareum Holdings plc
06/06/2017
The specialist cancer drug discovery and development business yesterday flagged the progress announced by its licensing partner, Sierra Oncology’s (NASDAQ: SRRA) on the two ongoing Phase 1 trials...

Latest discussion posts More

  • Dropping back

    This will not daily climb post latest rns
    5-Jun-2017
    clockwurktangerine
  • 2017

    No more spikes. No more deals...
    9-May-2017
    clockwurktangerine
  • Expectation

    Moved sp 0.2 to about 0.8 US deal and payments up to 1.2 but it has not held.... Deal on spikes...
    31-Mar-2017
    clockwurktangerine

Users' HoldingsMore

Users who hold Sareum Holdings also hold..
RANGE RES.18%
LLOYDS GRP.16%
ROCKHOPPER13%
SOLO OIL12%
GULF KEYSTONE11%

Codes & Symbols

ISINGB00B02RFS12
SymbolsSAR, LSE:SAR, SAR.L, SAR:LN, LON:SAR, XLON:SAR